

MIV Global Medtech Fund

Sub-Fund of an investment company with variable capital SICAV



Monthly report September 2022

Marketing document for private and institutional investors

Facts Fund class P2

Net Asset Value per Fund share EUR	2'074.06
Assets EUR m (all Fund classes)	2'516
Investment level	100%
Liquidity	0%

Industry breakdown

In-vitro Diagnostics	11%
Disposable Medical Supplies	8%
Hospital Equipment	7%
Ophthalmology	7%
Diabetes	6%
Surgical Instruments	6%
Endoscopy	5%
Orthopaedics	5%
Transcatheter heart valve	5%
Other Medical Technology Sectors	40%


Holdings

Abbott Laboratories	10%	HOYA	3%
Medtronic	9%	IDEXX Laboratories	3%
Intuitive Surgical	7%	Baxter	3%
Stryker	7%	Align Technology	2%
Edwards Lifesciences	6%	Thermo Fisher Scientific	2%
Boston Scientific	5%	Danaher	2%
Becton Dickinson	5%	Steris	2%
Alcon	4%	Straumann	2%
ResMed	4%	Sonova	2%
DexCom	3%	18 small holdings	19%

Currency breakdown

USD	79%	DKK	3%
JPY	8%	EUR	2%
CHF	7%	GBP	1%

Performance Fund class P2 EUR



Important legal information

Past performance is not a reliable indicator of current or future performance. Performance data take no account of the commissions and costs charged when units are issued and redeemed. The return of the Fund may go down as well as up due to changes in rates of exchange between currencies.

Company Headlines

The environment for medical device companies has been ambivalent since the start of the year. While end markets for many industry suppliers are in good shape, firms are facing higher costs for freight, raw materials, semi-finished products and electronic components, as well as disrupted supply chains, staff shortages in hospitals and rising wages. Added to this for US companies, which account for more than 80% of the MIV Global Medtech Fund assets, is the unfavourable exchange rate environment. We met with a dozen portfolio companies and their competitors at a healthcare conference in Boston in the month under review. Encouragingly, discussions with the management of these firms produced some positive results. There was confirmation that end markets are in good shape. The companies are applying various measures to adapt to the conditions characterised by high inflation. For example, a growing number of firms have been able to achieve price increases of – in some cases – up to 3%. Contrary to the widespread fears of a sustained negative trend for this environment, the conference participants reported diminishing rising costs as well as improved supply chains, and thus an improving outlook for margins and earnings performance. Accordingly, we expect the weighted earnings growth of the fund portfolio to accelerate from around 5% in the current year to a high single-digit percentage rate next year, and to return to the historic double-digit percentage growth level in 2024.

Stock market developments in the first five months of this year were marked by the sharp rise in inflation and the resulting interest rate turnaround, as a consequence of which the equity markets suffered substantial losses. A trend reversal set in in mid-June, which saw global indices increase by around 15%. These gains were eroded again over the last six weeks due to the persistently high inflation rates on both sides of the Atlantic and in other parts of the world, which forced the central banks to take further decisive measures and make a drastic U-turn following years of ultra-expansionary monetary policy. This brought to the fore concerns of a global economic slowdown and a growing probability of recession. Thanks to stable demand, as it is largely non-cyclical, the medical device industry has held up well in this type of environment in the past. Given the probable rising earnings growth rates of medical device firms in the coming two years and the expected comparatively strong declines in many cyclical sectors as well as the now significantly more attractive valuation, the medical device sector should gradually regain favour with investors, notably in a challenging economic environment.

Performance in EUR	September	2022	1 year	3 years	5 years	10 years	Inception
MIV Global Medtech Fund P2	-5.7%	-25.4%	-21.9%	4.4%	46.6%	231.5%	396.5%
Benchmark *	-5.2%	-23.0%	-19.8%	12.7%	72.8%	293.6%	407.2%
MSCI World Index	-6.9%	-13.4%	-4.9%	27.2%	56.2%	186.4%	274.6%
			10.17-9.18	10.18-9.19	10.19-9.20	10.20-9.21	10.21-9.22
MIV Global Medtech Fund P2			28.5%	9.3%	6.1%	25.9%	-21.9%
Benchmark *			32.1%	16.1%	11.2%	26.5%	-19.8%
MSCI World Index			13.2%	8.5%	2.6%	30.3%	-4.9%

* MSCI World Healthcare Equipment & Supplies

Investments in medical devices

Investment Strategy

The MIV Global Medtech Fund invests globally in listed medical device companies. The investment process is based on a combined top-down / bottom-up approach. Against the background of the particular macroeconomic environment, the most interesting markets and companies are determined based on an intensive primary analysis. Alongside an attractive valuation, a strong market position, good growth potential, excellent products, sustainable profitability and high-quality management are the decisive parameters for investment. The consideration of sustainability criteria (ESG) is integrated in the research, analysis and investment process. Risks are managed by means of portfolio diversification. The portfolio of the MIV Global Medtech Fund is structured more defensively or cyclically in the best possible anticipation of economic trends, with a view to achieving a higher return than the benchmark and the general market indices.

Benefits

Owing to demographic trends and the desire for quality of life and mobility, the medical device industry is a long-term growth market. Emerging markets will have a positive impact on the medical device industry's future growth thanks to the state-backed expansion of their healthcare systems. Medical device suppliers' priority is the development of innovative, minimally invasive products. These are beneficial for patients and cost efficient for the healthcare system due to shorter convalescence periods. Most interesting from an investor's perspective are the industry's high growth rates, above-average profitability and oligopolistic market structures with their high entry barriers for new competitors. Even in a demanding environment, significant product innovations continue to offer attractive growth prospects.

Risks

The MIV Global Medtech Fund invests in equity securities and may therefore be subject to high fluctuations in value. For this reason, a medium-term to long-term investment horizon and corresponding risk tolerance and capacity are required for an investment into this Sub-Fund. As the MIV Global Medtech Fund pursues an active management style, the Sub-Fund's performance can deviate substantially from that of its reference index. The focus on equity securities of medical device companies exposes the Sub-Fund potentially to additional specific risks of this area of the healthcare industry. The Sub-Fund may, for the purpose of hedging and the efficient management of the portfolio, make use of derivatives, which can lead to additional risks (particularly counter party risk). All investments are subject to market fluctuations. Every Fund has specific risks, which can significantly increase under unusual market conditions.

Information

Website	www.mivglobalmedtech.com
Legal structure	Sub-Fund of Variopartner SICAV, an investment fund under Luxembourg law
Fund class	P2 (EUR) accumulation / ISIN: LU0329630130 / Swiss Valor Number: 3535023 / WKN: A0NETR
Subscription/redemption	On every bank working day in Luxembourg until 3.45 p.m. at net asset value (no calculation of net asset values on bank/stock exchange holidays in Luxembourg and/or the US)
Management fee	1.4% p.a.
Total Expense Ratio (TER) as of 31.12.2021	1.54%
Launch of fund	11 March 2008
Launch of fund class P2	13 January 2010
Close of financial year	30 June
Benchmark	MSCI World Healthcare Equipment & Supplies
Reporting of the Portfolio manager	Monthly, semester and yearly report
Fund price monitoring	www.mivglobalmedtech.com / www.swissfunddata.ch / www.fundinfo.com Bloomberg: VARMVP2 LX / Reuters: LU0329630130.LUF / Neue Zürcher Zeitung
Portfolio manager	MIV Asset Management AG, Feldeggstrasse 55, CH-8008 Zurich, info@mivglobalmedtech.ch Contact: Jürg Nagel, Christoph Gubler, Giuseppe Di Benedetto, Phone +41 44 253 64 11
Management company	Vontobel Asset Management S.A., 18, rue Erasme, L-1468 Luxembourg
Representative in Switzerland	Vontobel Fonds Services AG, Gotthardstrasse 43, CH-8022 Zurich
Custodian/Administrator	RBC Investor Services Bank S.A., 14, Porte de France, L-4360 Esch-sur-Alzette
Auditor	Ernst & Young S.A., 35E, Avenue John F. Kennedy, L-1855 Luxembourg
Minimum subscription	none
Admissions to distribution	Switzerland, Germany, Austria, Liechtenstein, Luxembourg, France, Italy, Spain, Finland, Norway, Sweden, Singapore (restricted scheme)
Distribution restrictions	USA / US persons

Sustainability profile - ESG

MIV Asset Management identifies, monitors and mitigates ESG risks that are, or could become, material to the performance of medical technology companies. The approach is based on the following factors:

- **Integration:** The consideration of sustainability criteria (ESG) is integrated into the research, analysis and investment process.
- **Exclusion:** The MIV Global Medtech Fund invests globally in listed medical technology companies. Investments in controversial industries are excluded (in particular pornography, alcohol, cluster munitions, gambling, landmines, mining, nuclear power, tobacco and armament dealing).
- **Best-in-class approach:** Diversified equity portfolio with below-average ESG risk. Investments with a Sustainability Controversy Rating of 5 (high) as well as a Sustainability ESG Risk Rating above 40 (severe) are excluded.
- **Dialogue:** MIV Asset Management maintains close and regular contact with the management of actual and potential investments, amongst other, with the goal of improving ESG practices and disclosure at these companies.
- **Ownership rights:** The active ownership approach includes exercising the MIV Global Medtech Fund's voting rights. These are delegated to the ISS proxy with Sustainability Policy. In case of controversial decisions, MIV Asset Management gets directly involved.

- ☑ The MIV Global Medtech Fund is classified as a financial product under **EU SFDR Article 8**
- ☑ MIV Asset Management is a signatory to the **UN Principles for Responsible Investment**
- ☑ The MIV Global Medtech Fund's investments support **UN Sustainable Development Goals 3, 8, 9 and 10**
- ☑ MIV Asset Management works together with the proxy ISS with **Sustainability Policy**
- ☑ The MIV Global Medtech Fund has an **above-average MSCI ESG score (10.0)** and **MSCI ESG rating (AAA)**
- ☑ The MIV Global Medtech Fund has an **above-average Sustainability ESG profile**

Investments in medical devices

Glossary

Benchmark	An index, which is used as a reference for the measurement of the performance of the Fund.
Inception	Launch date of the Fund and/or the Fund class.
Management fee	Portfolio manager's fee for the management and the distribution of the Fund.
NAV	Net Asset Value: total Fund assets divided by total number of Fund shares outstanding.
TER	Total Expense Ratio: sum of all fees and costs, which are charged to the Fund on a continuous basis.

Important legal information

MIV Global Medtech Fund is a Sub-Fund of Variopartner SICAV, an investment fund under Luxembourg law. This document is for information purposes only and nothing contained in this document should constitute a solicitation, or offer, or recommendation, to buy or sell any investment instruments, to effect any transactions, or to conclude any legal act of any kind whatsoever. This document has been produced by MIV Asset Management AG ("MIV AM"). It is explicitly not the result of a financial analysis and therefore the "Directives on the Independence of Financial Research" of the Swiss Bankers Association is not applicable. Although MIV AM believes that the information provided in this document is based on reliable sources, it cannot assume responsibility for the quality, correctness, timeliness or completeness of the information contained in this report. Any companies described in this document may or may not currently represent a position in the portfolio of the MIV Global Medtech Fund. Any projections, forecasts or estimates contained in this document are based on a variety of estimates and assumptions. There can be no assurance that the estimates or assumptions made will prove accurate, and actual results may differ materially.

Subscriptions of shares of the Sub-Fund should in any event be made solely on the basis of the current sales prospectus, the current Key Investor Information Document (KIID), the current articles of association and the most recent annual and semi-annual reports of Variopartner SICAV. For more details regarding the potential risks of an investment in Sub-Funds of Variopartner SICAV, please refer to the current sales prospectus. Interested parties may obtain the abovementioned documents free of charge from the Portfolio manager: MIV Asset Management AG, Feldeggstrasse 55, CH-8008 Zurich, the representative in Switzerland: Vontobel Fonds Services AG, Gotthardstrasse 43, CH-8022 Zurich, the paying agent in Switzerland: Bank Vontobel AG, Gotthardstrasse 43, CH-8022 Zurich, the European facilities agent for Germany, Finland, France, the Netherlands and Norway: PwC Société coopérative – GFD, 2, rue Gerhard Mercator B.P. 1443, L-1014 Luxembourg, lu_pwc.gfd.facsvs@pwc.com, the financial and central administration agent in France: BNP Paribas Securities Services S.A., 3, Rue d'Antin, F-75002 Paris, the Austrian Facility: Erste Bank der oesterreichischen Sparkassen AG, Am Belvedere 1, A-1100 Vienna, the information agent in Liechtenstein: LLB Fund Services AG, Äulestrasse 80, FL-9490 Vaduz, the paying agents in Italy: RBC Investor Services Bank, Via Vittor Pisani, 26, I-20124 Milan, Allfunds Bank, S.A.U., Via Bocchetto, 6, I-20123 Milan, the paying agent in Sweden: Skandinaviska Enskilda Banken AB (publ), Investor Services/Paying Agent, AS-12, Råsta Strandväg 5, SE-169 79 Solna, from the offices of the Fund: Variopartner SICAV, 11-13, Boulevard de la Foire, L-1528 Luxembourg. They may also be downloaded from the website www.mivglobalmedtech.com.

This Sub-Fund is not available to retail investors in Singapore. It is accepted as restricted scheme by the Monetary Authority of Singapore (MAS) and may only be offered to certain prescribed persons on certain conditions as provided in the "Securities and Futures Act", Chapter 289 of Singapore.

This Sub-Fund is not authorised by the Securities and Futures Commission of Hong Kong. It may only be offered to those investors qualifying as professional investors under the Securities and Futures Ordinance. The contents of this document have not been reviewed by any regulatory authority in Hong Kong.

Past performance is not a reliable indicator of current or future performance. Performance data take no account of the commissions and costs charged when units are issued and redeemed. The return of the Fund may go down as well as up due to changes in rates of exchange between currencies.

